Pharmacokinetic andIn VivoEfficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice
2013 ◽
Vol 57
(10)
◽
pp. 5138-5140
◽
Keyword(s):
ABSTRACTMycobactin biosynthesis inMycobacterium tuberculosisfacilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5′-O-(N-salicylsulfamoyl)adenosine] inhibitsM. tuberculosisgrowthin vitrounder iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl-AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibitedM. tuberculosisgrowth in the mouse lung, providing the firstin vivoproof of concept for this novel antibacterial strategy.
2015 ◽
Vol 59
(8)
◽
pp. 4446-4452
◽
Keyword(s):
2014 ◽
Vol 58
(6)
◽
pp. 3312-3326
◽
2011 ◽
Vol 56
(2)
◽
pp. 731-738
◽
2015 ◽
Vol 59
(8)
◽
pp. 4457-4463
◽
2014 ◽
Vol 59
(1)
◽
pp. 136-144
◽